- Results from the 2005 National Survey on Drug Use and Health: national findings.Accessed April 10, 2007)
- Increasing deaths from opioid analgesics in the United States.Pharmacoepidemiol Drug Safety. 2006; 15: 618-627
- Adverse effects in children after unintentional buprenorphine exposure.Pediatrics. 2006; 118: 1746-1751
- The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®).Pain Med. 2007; 8: 157-170
- Instructions for the American Association of Poison Control Centers Toxic Exposure Surveillance System (2001).Accessed July 5, 2007)
- The effect of FDA approval of a generic competitor to OxyContin® (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.Drug Alcohol Depend. 2006; 84: 182-187
- Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.Clin Toxicol. 2007; 45: 144-151
- Clinical validation of poison control center (PCC) intentional exposure cases involving prescription opioids.Am J Drug Alcohol Abuse. 2006; 32: 465-478
- Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) drug label.Accessed August 1, 2008.)
Supervising editor: Steven M. Green, MD
Dr. Green was the supervising editor on this article. Dr. Dart did not participate in the editorial review or decision to publish this article.
Author contributions: JEB and RCD conceived and designed the study and obtained funding through an unrestricted educational grant. The RADARS System Poison Center Investigators were responsible for collecting the data, performing quality control checks on the data, and commenting on the article. EC analyzed the data. Each author was responsible for drafting different sections of the article and contributed substantially to the revisions of the article as a whole. JEB takes responsibility for the paper as a whole.
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA, supported these analyses through an unrestricted educational grant but did not participate in the data collection, analysis, or preparation of the article. Denver Health—Rocky Mountain Poison & Drug Center (RMPDC) is a nonprofit public hospital that operates the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System. Data presented are from poison centers participating in this system. RADARS System is supported by several subscribers from the pharmaceutical industry.
Publication dates: Available online September 2, 2008.